Your browser doesn't support javascript.
loading
Treatment persistence among bio-naïve patients with Crohn's disease initiated on ustekinumab or adalimumab.
Zhdanava, Maryia; Ding, Zhijie; Manceur, Ameur M; Muser, Erik; Lefebvre, Patrick; Holiday, Christopher; Lafeuille, Marie-Hélène; Pilon, Dominic.
Afiliación
  • Zhdanava M; Analysis Group, Inc., Montreal, Quebec, Canada.
  • Ding Z; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Manceur AM; Analysis Group, Inc., Montreal, Quebec, Canada.
  • Muser E; Janssen Scientific Affairs, LLC, Horsham, PA, USA.
  • Lefebvre P; Analysis Group, Inc., Montreal, Quebec, Canada.
  • Holiday C; Analysis Group, Inc., Montreal, Quebec, Canada.
  • Lafeuille MH; Analysis Group, Inc., Montreal, Quebec, Canada.
  • Pilon D; Analysis Group, Inc., Montreal, Quebec, Canada.
Curr Med Res Opin ; 39(4): 533-543, 2023 04.
Article en En | MEDLINE | ID: mdl-36752586
OBJECTIVES: To compare persistence and describe dose titration among bio-naïve patients with Crohn's disease (CD) initiated on ustekinumab or adalimumab. METHODS: Bio-naïve adults with CD who initiated ustekinumab or adalimumab (index date) from 23 September 2016 (ustekinumab US approval for CD) to 1 August 2019 were selected from IQVIA PharMetrics Plus. Cohorts were balanced on baseline characteristics measured over 12 months pre-index using inverse probability of treatment weights. Persistence was defined as no gaps (ustekinumab: >120 days; adalimumab: >60 days) between days of supply. Dose escalation was defined as ≥2 consecutive sub-cutaneous claims 100% above the US label daily dose in the maintenance phase; de-escalation was a return to the daily dose for ≥2 consecutive claims. Outcomes were described using weighted Kaplan-Meier models; persistence outcomes were compared using Cox's proportional hazards models. RESULTS: At 12 months post-index, patients in the ustekinumab (n = 948) versus adalimumab (n = 4143) cohort had a significantly higher rate of persistence on index biologic (hazard ratio [HR] 1.50; 95% confidence interval [CI]: 1.29-1.74). A total of 830 (87.6%) patients in the ustekinumab cohort and 3713 (89.6%) in the adalimumab cohort began the maintenance phase; within 12 months, 11.2% and 16.9%, underwent a dose escalation, and 26.6% and 6.3%, respectively, subsequently de-escalated to the per US label daily exposure. CONCLUSIONS: Bio-naïve patients with CD initiated on ustekinumab were more persistent than patients initiated on adalimumab; moreover, these patients had numerically lower dose escalation and higher de-escalation rates than patients initiated on adalimumab. Findings support the use of ustekinumab as a first-line treatment for bio-naïve patients with CD.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Crohn Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Curr Med Res Opin Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Enfermedad de Crohn Tipo de estudio: Prognostic_studies Límite: Adult / Humans Idioma: En Revista: Curr Med Res Opin Año: 2023 Tipo del documento: Article País de afiliación: Canadá Pais de publicación: Reino Unido